Researchers released two high-resolution methods this week that sharpen detection of off-target edits produced by DNA base editors. A tailored genome-wide assay (CHANGE-seq-BE) provides sensitive, unbiased mapping of base-editor-induced edits across the genome, while a separate method from St. Jude Children's Research Hospital offers a practical approach to identify small off-target sites that pose clinical safety risks. Both teams published detailed protocols and validation data, enabling laboratories and biotech developers to benchmark editor variants and screening strategies. CHANGE-seq-BE emphasizes genome-scale sensitivity; the St. Jude approach focuses on clinical applicability for small, hard-to-detect off-targets. For readers: base editors alter single DNA bases without double-strand breaks — off-target detection is essential for clinical safety assessments.